Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients
Mysa Saad/LinkedIn
Apr 16, 2026, 04:13

Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients

Mysa Saad, Internal Medicine Resident shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:

”Our new study published in Thrombosis Research:

In ambulatory patients with cancer on apixaban thromboprophylaxis:

  • Concurrent antiplatelet/NSAID use increases clinically relevant bleeding (HR 1.80)
  • Antiplatelets were the main driver of increased bleeding risk (HR 2.02)
  • NSAIDs did not have a significant impact on bleeding risk
  • No significant reduction in VTE

These results highlight the need to carefully reassess indications for concurrent antiplatelet agents/NSAIDs when considering apixaban thromboprophylaxis in patients with cancer.”

Title: Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial

Authors: Mysa Saad, Tzu-Fei Wang, Ranjeeta Mallick, Danny Hill, Alejandro Lazo-Langner, Vicky Tagalakis, Philip S. Wells, Marc Carrier

Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients

Stay updated on all scientific advances with Hemostasis Today.

Alejandro Lazo-Langner Antiplatelet Apixaban bleeding disorders cancer Danny Hill Health Hematology Hemostasis Hemostasis News Hemostasis Today Marc Carrier Medicine Mysa Saad NSAID Philip S. Wells Ranjeeta Mallick Tzu-Fei Wang Vicky Tagalakis VTE
NewsFeed